Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Major Shareholder Buys $186,389.40 in Stock

Atara Biotherapeutics, Inc. (NASDAQ:ATRA - Get Free Report) major shareholder Innovation Ltd Panacea purchased 19,335 shares of Atara Biotherapeutics stock in a transaction that occurred on Thursday, July 17th. The stock was acquired at an average price of $9.64 per share, for a total transaction of $186,389.40. Following the transaction, the insider directly owned 1,350,000 shares of the company's stock, valued at $13,014,000. The trade was a 1.45% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Large shareholders that own 10% or more of a company's stock are required to disclose their transactions with the SEC.

Atara Biotherapeutics Trading Up 13.2%

ATRA traded up $1.52 on Tuesday, hitting $13.02. The company had a trading volume of 149,507 shares, compared to its average volume of 117,629. The firm has a market cap of $77.60 million, a P/E ratio of -3.50 and a beta of 0.18. Atara Biotherapeutics, Inc. has a 1 year low of $5.01 and a 1 year high of $18.71. The company's fifty day moving average price is $8.15 and its 200 day moving average price is $8.06.

Atara Biotherapeutics (NASDAQ:ATRA - Get Free Report) last released its quarterly earnings data on Thursday, May 15th. The biotechnology company reported $3.50 earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.07) by $6.57. The business had revenue of $98.10 million during the quarter, compared to analysts' expectations of $4.30 million. On average, analysts predict that Atara Biotherapeutics, Inc. will post -10.39 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. EcoR1 Capital LLC raised its holdings in Atara Biotherapeutics by 7.7% in the 1st quarter. EcoR1 Capital LLC now owns 573,183 shares of the biotechnology company's stock valued at $3,405,000 after acquiring an additional 41,049 shares in the last quarter. Staley Capital Advisers Inc. grew its position in Atara Biotherapeutics by 60.0% during the first quarter. Staley Capital Advisers Inc. now owns 80,000 shares of the biotechnology company's stock worth $475,000 after buying an additional 30,000 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Atara Biotherapeutics in the 4th quarter valued at $48,000. Cubist Systematic Strategies LLC acquired a new stake in Atara Biotherapeutics in the fourth quarter valued at $169,000. Finally, Citadel Advisors LLC lifted its position in Atara Biotherapeutics by 2.6% in the 4th quarter. Citadel Advisors LLC now owns 267,353 shares of the biotechnology company's stock valued at $3,558,000 after acquiring an additional 6,873 shares in the last quarter. Institutional investors and hedge funds own 70.90% of the company's stock.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.